ReviewMolecules (Basel, Switzerland)2015
Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 99 citations in OpenAlex.
- Therapeutic efficacy of hispidulin-loaded carboxymethyl cellulose nanoparticles against mammary carcinogenesis through ROS-mediated apoptosis and tissue remodelling.Frontiers in oncology · 2026Article
- Polyphosphazene-Based Nanotherapeutics.Journal of functional biomaterials · 2025Review
- Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives.Frontiers in pharmacology · 2025Review
- Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy.Discover oncology · 2024Review
- Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.Cancer medicine · 2024Article
- Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine.Medical oncology (Northwood, London, England) · 2023Review
- Anticancer Potential of Sulfonamide Moieties via In-Vitro and In-Silico Approaches: Comparative Investigations for Future Drug Development.International journal of molecular sciences · 2023Article
- Nanoparticles of folic acid-methyl-β-cyclodextrin (FA-MβCD)/adamantane-albumin exhibit enhanced antitumor activity compared with FA-MβCD alone.FEBS open bio · 2023Article
- Folate Conjugated Polyethylene Glycol Probe for Tumor-Targeted Drug Delivery of 5-Fluorouracil.Molecules (Basel, Switzerland) · 2022Article
- Circumventing Doxorubicin Resistance Using Elastin-like Polypeptide Biopolymer-Mediated Drug Delivery.International journal of molecular sciences · 2022Article
- Apoptosis Induction, Cell Cycle Arrest and Anti-Cancer Potential of Tamoxifen-Curcumin Loaded Niosomes Against MCF-7 Cancer Cells.Iranian journal of pathology · 2022Article
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component.Molecules (Basel, Switzerland) · 2021Review
- Nanosystems Applied to HIV Infection: Prevention and Treatments.International journal of molecular sciences · 2020Review
- Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria.Pharmaceutics · 2020Review
- Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs.Nanomaterials (Basel, Switzerland) · 2020Review
- Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.Drug delivery and translational research · 2020Review
- Polymeric persulfide prodrugs: Mitigating oxidative stress through controlled delivery of reactive sulfur species.ACS macro letters · 2020Article
- Polyvinyl Alcohol Carbazate as a Polymer-Based Antitumoral Agent.Frontiers in oncology · 2020Article
- Total drug quantification in prodrugs using an automated elemental analyzer.Drug delivery and translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of anticancer drugs have poor aqueous solubility, produce adverse effects in healthy tissue, and thus impose major limitations on both clinical efficacy and therapeutic safety of cancer chemotherapy. To help circumvent problems associated with solubility, most cancer drugs are now formulated with co-solubilizers. However, these agents often also introduce severe side effects, thereby restricting effective treatment and patient quality of life. A promising approach to addressing problems in anticancer drug solubility and selectivity is their conjugation with polymeric carriers to form polymer-based prodrugs. These polymer-based prodrugs are macromolecular carriers, designed to increase the aqueous solubility of antitumor drugs, can enhance bioavailability. Additionally, polymer-based prodrugs approach exploits unique features of tumor physiology to passively facilitate intratumoral accumulation, and so improve chemodrug pharmacokinetics and pharmacological properties. This review introduces basic concepts of polymer-based prodrugs, provides an overview of currently emerging synthetic, natural, and genetically engineered polymers that now deliver anticancer drugs in preclinical or clinical trials, and highlights their major anticipated applications in anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.